The Oxford Vaccine Group is recruiting infants aged 4 – 7 months to a type 1 diabetes prevention trial. POInT (Primary Oral Insulin Trial) is recruiting infants who were screened for diabetes at birth through the INGR1D Study and have been found to be at high risk for developing diabetes.

POInT examines whether the development of type 1 diabetes can be prevented in children with an increased risk of type 1 diabetes through preventive treatment with oral insulin. The trial’s aim is to see if we can train the immune system so that it tolerates its own insulin. The overall aim is to develop ways to prevent diabetes.